Synutra International announces that further Chinese government testing of its infant formula products confirms that products compliant with federal standards

Nevin Barich

Nevin Barich

Jan 20, 2012 – PRNewswire

QINGDAO, China and ROCKVILLE, Maryland , January 20, 2012 (press release) – Synutra International, Inc. (NASDAQ: SYUT - News), ("Synutra" or the "Company"), which owns subsidiaries in China that produce, market and sell nutritional products for infants, children and adults, today announced the final findings by government authorities regarding the case involving the twin infants from Jiangxi Province. The Jiangxi Province Center for Disease Control and Prevention and the Jiangxi Dairy Quality Supervision and Inspection Center ("the Authorities") have performed two separate rounds of testing, which both confirmed the preliminary findings announced on January 13, 2012 from the People's Government of Duchang County that cleared Synutra products. The Authorities stated that samples in both additional tests were collected directly from the family of the deceased infant and from the retail store where the family bought the products and concluded that the samples are compliant with all eleven national standards, including level of coliform bacteria and total bacterial count. The Authorities also tested the residential well water from the family and found that both coliform bacteria levels and total bacterial count exceeded national standards. The Authorities had also previously released the attending physician's diagnostic records that determined the infant death was due to body overheating (hyperthermia) and multi-functional organ failure and that both the death of the male infant and the sickness of his twin sister were not due to food poisoning or related to food.

Mr. Weiguo Zhang, President and interim CFO of Synutra, commented, "We are pleased that our product and brand have been cleared of any responsibility in this tragic situation. We are currently assessing the impact of this event on our business. We will inform our investors when we have a clearer picture of the overall operational effect in the coming weeks. At this point, our sales and earnings estimates for the quarter ended December 31, 2011 remain unchanged. We plan to announce the results of third quarter of fiscal year 2012 in the second week of February, and we estimate the sales revenue to be within a range of $90 to $93 million and net income in a range of $9 to $10 million."

Please contact the Company at with any further inquiries.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT - News) is a leading infant formula company in China. It principally produces, markets and sells its products through its operating subsidiaries under the "Shengyuan" or "Synutra" name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering all provinces and provincial-level municipalities in mainland China As of September 30, 2011, this network comprised over 670 independent distributors and over 900 independent sub-distributors who sell Synutra products in over 72,000 retail outlets.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.


About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025 795

+1 (310) 558 0008
+1 (310) 558 0080 (FAX)

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.